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Abstract
This review covers the diverse topic of neuroendocrine neoplasms (NENs), a relatively rare and heterogeneous
tumor type, comprising ~2% of all malignancies, with a prevalence of b200,000 in the United States, which makes
it an orphan disease (Basu et al., 2010).1 For functional purposes, NENs are divided into two groups on the basis of
clinical behavior, histology, and proliferation rate: well differentiated (low grade to intermediate grade)
neuroendocrine tumors and poorly differentiated (high grade) neuroendocrine carcinoma (Bosman et al.,
2010),2; this histological categorization/dichotomization is highly clinically relevant with respect to impact on
treatment and prognosis even though it is not absolute since a subset of tumors with a low-grade appearance
behaves similarly to high-grade lesions. Given the relative dearth of evidenced-based literature about this orphan
disease as a whole (Modlin et al., 2008),3 since the focus of most articles is on particular anatomic subtypes of
NENs (i.e., gastroenteropancreatic or pulmonary), the purpose of this review is to summarize the presentation,
pathophysiology, staging, current standard of care treatments, and active areas of current research.
Neoplasia (2017) 19, 991–1002
Introduction
Neuroendocrine neoplasms (NENs) are a heterogeneous group of
malignancies with a varied, confusing histology and nomenclature to
match. The term “neuroendocrine” is applied to widely dispersed cells
with “neuro” and “endocrine” properties.1 The “neuro” property is
based on the identification of dense core granules (DCGs4) that are
similar to DCGs present in serotonergic neurons, which store
monoamines. (Unlike neurons, however, NE cells do not contain
synapses.) The “endocrine” property refers to the synthesis and
secretion of these monoamines.5 The neuroendocrine (NE) system
includes endocrine glands, such as the pituitary, the parathyroids, and
the NE adrenal, as well as endocrine islet tissue embedded within
glandular tissue (thyroid or pancreatic) and scattered cells in the
exocrine parenchyma, such as endocrine cells of the digestive and
respiratory tracts, which belong to what is known as the diffuse
endocrine system.5 Historically, well-differentiated NENs are
referred to as carcinoid tumors, a term that has led to errors in
communication and confusion, as discussed below.
Given the body-wide distribution of NE cells, NENs have been
described in the central nervous system, respiratory tract, the larynx,
gastrointestinal (GI) tract, thyroid, skin, breast, and urogenital system.3
The GI tract and lungs are the most common primary tumor sites.6
In current practice, based on clinical behavior, histology, and
proliferation rate, NENs are generally categorized, similar to lymphomas,
as low-grade indolent tumors versus high-grade aggressive carcinomas2;
this dichotomization is highly relevant for prognosis and treatment
choice.7 The indolent tumors, befitting the “indolent” descriptor, tend to
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follow a prolonged clinical course with a low risk of distant metastases
even in the absence of treatment, whereas the aggressive carcinomas,
closely related to pulmonary small-cell carcinoma, are associated with
rapid progression and poor long-termprognosis.8 However, an important
point, emphasized in the review, is that this low-grade/high-grade
dichotomization is not absolute since some histologic low-grade tumors
may behave more like advanced progressive carcinomas9 that require
systemic treatment with cytotoxic chemotherapy. Paradoxically, the
rapidly dividing cells of high-grade aggressive carcinomas are potentially
eradicable with multiagent chemotherapy, while the slow mitotic rate of
the indolent lymphomas generally makes them resistant to treatment.10
The clinical rule of thumb (with exceptions) is that low-grade tumors
are managed with surgical resection11 while unresectable and
symptomatic disease is treated with somatostatin analogs and/or
interferon-α even though tumor regression with these agents is
rare.12 In contrast, etoposide/platinum-based chemotherapy is the
mainstay of treatment for high-grade or metastatic neuroendocrine
carcinomas (NECs)13; however, other agents and modalities are under
active investigation. They include targeted agents like sunitinib and
everolimus and the experimental epi-immunologic agent, RRx-001, as
well as evolving modalities like peptide receptor targeted therapies and
radioembolization. This review covers the presentation, pathophysiol-
ogy, staging, current standard of care treatments, and active areas of
current research for neuroendocrine tumors (NETs) and carcinomas.
Epidemiology
NETs account for about 0.5% of all newly diagnosed malignancies.14
The incidence, which is on the rise, possibly due to improved awareness,
is approximately 5.86/100,000 per year14 with a female preponderance
of around 2.5:1.15 The prevalence, which is estimated at 103,312 cases
in the United States,16 meets criteria for orphan disease status3,17:
b200,000 for the whole population of the United States.18
The most frequent primary sites are the gastrointestinal tract
(62%-67%) and the lung (22%-27%). Twelve percent to 22% of
patients are metastatic at presentation.14 The majority of NENs arise
sporadically, but association with the multiple endocrine neoplasia
type 1 syndrome and familial clustering is recognized.14 Smoking or
alcohol consumption does not appear to increase the risk of NENs.14
GI NETs are more common in African Americans than whites,19
while bronchial carcinoids predominantly affect Caucasians.20
Rare diseases, like NETs, are sometimes classified as “zebras” on the
basis of the aphorism “when you hear hoofbeats think horses not zebras”
frequently invoked on the wards as a reminder or, more likely, a rebuke
to the overzealous medical student that common diseases occur
commonly while rare diseases or “zebras” occur rarely. Accordingly,
perhaps in somewhat meta-ironic reference to this esoteric clinical
aphorism (meta-ironic because, outside of the medical circle,
presumably few have knowledge of this statement on and about rarity),
the zebra has been adopted as the symbol for neuroendocrine awareness.
Histology
Well-differentiated NET cells, which produce abundant secretory
granules with intense immunoexpression of neuroendocrine markers
such as chromogranin A (CgA) and synaptophysin (Syn), are
characteristically arranged in a well-developed “organoid” or neuroen-
docrine shape with nesting, trabecular, or gyriform/serpentine growth
patterns.21 The tumor cells are small with relatively uniform round to
oval nuclei, inconspicuous nucleoli, and a fine to coarsely granular
chromatin pattern often described as “salt and pepper”.22
In contrast, NECs demonstrate a solid “sheetlike” proliferation of
tumor cells with irregular nuclei, high mitotic features, and less
cytoplasmic secretory granules.21 Immunocytochemical staining
patterns for neuroendocrine markers are more limited (diffuse
expression of Syn, faint or focal staining for CgA).22 Up to 40% of
NECs contain elements of non-neuroendocrine histology; by
definition, the neuroendocrine component has to exceed 30% for
the tumor to be called an NEC; otherwise, it is classified as a mixed
adenoneuroendocrine carcinoma.23
Terminology and Classification
Confusion and obfuscation have surrounded the terminology of NETs
ever since the pathologist Siegfried Oberndorfer invented the word
carcinoid at the turn of the 20th century to mean “carcinoma-like”24;
the description was in reference to the benign behavior of
morphologically atypical small bowel tumors25 composed of
argentaffin-positive and argyrophilic cells, so-called because they take
up and reduce silver salts.
The word carcinoid has been criticized26 1) as an imprecise, generic,
“non–user friendly” and obsolete “catch all”27 that lumps together
different tumors distinct in their etiology, prognosis, and management,
leading to terminological confusion and diagnostic unreliability, and 2)
as a straight misnomer 28 because despite the presence of
innocuous-appearing cells with uniform nuclei and few mitoses, these
tumors, to different degrees, behave malignantly (not benignly as
Oberndorfer mistakenly assumed) with metastasis, local invasion, and
recurrence after resection. The persistence of the term carcinoid and the
confusion (and contention) surrounding its usage may be related to the
lack of consensus and homogeneity with regard to taxonomy,
terminology, and definitions of these loosely related tumors, especially
in theGI and respiratory tracts, as detailed below; the semantic issues are
magnified by the use of an alphabet soup of acronyms and a plethora of
terms synonymous with carcinoid including APUDoma, argentaffi-
noma, enteroendocrine, tumors of the diffuse endocrine system,
endocrine tumor, and argyrophilic cell carcinoma.29
In 1928, Gosset and Masson characterized carcinoids as NETs on
the basis of amine uptake and decarboxylation properties.30
In 1963, Williams and Sandler classified carcinoids according to
the embryonic divisions of the digestive tract, that is, foregut,
(bronchopulmonary, stomach, duodenum, biliary, and pancreas),
midgut (jejunum, ileum, appendix, and proximal colon), and hindgut
(distal colon and rectum)27 (Figure 1).
In 1972, Arrigoni et al. characterized a histologic variant of typical
carcinoid tumor composed of large polymorphic nucleolated cells in
gland-like arrangement as “atypical carcinoid.”31
In 1980, the World Health Organization (WHO)32 applied the
term carcinoid to describe all NETs except pulmonary neuroendo-
crine tumors (pNETs), identified as a separate entity. However, this
WHO classification only managed to sow more terminological
confusion since pathologists, accordingly, applied the word carcinoid
to all tumors of the endocrine system, while clinicians in general
conflated it with the presence of carcinoid syndrome, 33 a
constellation34 of cutaneous and systemic signs and symptoms
including flushing, diarrhea, and bronchospasm associated with the
hypersecretion of vasoactive amines (e.g., serotonin and histamine) by
the carcinoid tumor.
In 1999, the Travis-WHO classification35 divided the spectrum of
pulmonary and thymic NE tumors into four subtypes characterized
by increasing aggressiveness: typical carcinoid tumors with a low
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grade and long life expectancy, atypical carcinoid tumor with an
intermediate differentiation and a more aggressive clinical course, and
large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung
carcinoma (SCLC) with a high grade and a dismal prognosis.36
In 2000, WHO prepared a revised gastroenteropancreatic (GEP)
classification that eschewed the term carcinoid in favor of NET and
identified three histologic categories irrespective of the site of origin37:
• Well-differentiated neuroendocrine tumor with probably benign
behavior
• Well-differentiated neuroendocrine tumor with uncertain behavior
• Poorly differentiated neuroendocrine carcinoma with high-grade
malignant behavior
In 2004, the WHO divided neoplasms of the lung and thymus
into three grades based on mitotic index and necrosis (Table 1).38
Grade 3 NECs predict the development of metastatic dissemina-
tion even in tumors that are initially clinically localized. The GEP
tract is the most common site for extrapulmonary NEC, accounting
for 35% to 55% of all NECs outside the lung.39
In 2010, the latest version of the WHO classification appeared,
which redefined the entire group of tumors as NENs. GI NENs were
subdivided according to their mitotic count or Ki67 index, associated
with cellular proliferation (Table 2).
In 2015, the National Comprehensive Cancer Network (NCCN)
recommended the inclusion of tumor differentiation, mitotic rate,
and Ki-67 in the pathology report with specification of the particular
classification and grading scheme to avoid confusion.40
In line with the NCCN recommendations, it is important to
highlight that (as with many tumor types) histologic grade does not
always correlate with clinical behavior; a subset of NENs with a
low-grade histologic appearance may behave aggressively with rapid
growth and metastases matching those of high-grade NEC.41
Therefore, in case of discordancy between differentiation and Ki-67
proliferation or when a purportedly low-grade tumor does not follow
the predicted indolent course, clinical judgment and gestalt, per the
NCCN, should trump histological appearance,42 which may lead to
treatment of certain “low-grade” tumors with platinum-doublet
chemotherapy.
In the absence of a simple, practical, and universally accepted
system of nomenclature and classification, entrenched terms such as
“carcinoid” and “atypical carcinoid” linger on especially in reference
to pulmonary NENs; therefore, despite all the attempts at
reclassification, familiarity with these older terms and histologic
categories even if they are potentially misleading and confusing is
beneficial.
Staging
No formal tumor-nodes-metastasis (TNM)–based staging systems
were in use for GEP neoplasms until the American Joint Committee
on Cancer formally adopted one in 2010 for all anatomic sites, which
parallels the European Neuroendocrine Tumor Society (ENETS)
TNM system published in 2006.43 Although the staging criteria for
both systems depend on assessment of size (T stage), the extent of
invasion, and its relationship to anatomical landmarks similar to the
staging of non-NECs of the same sites, differences between them,
most notably with regard to the classification of appendiceal and
pancreatic, complicate assessment. For pulmonary NENs, non–
small-cell lung cancer staging criteria are applied (seventh edition of
the TNM staging system).44 Currently, no specific TNM staging
system for thymic and urogenital NENs is in use.
Genetics
The majority of NENs are sporadic, but hereditary syndromes that
predispose to it include multiple endocrine neoplasia type 1
(MEN-1), MEN-2, von Hippel–Lindau (VHL) syndrome, neurofi-
bromatosis, and tuberous sclerosis.45,46 Mutations in the RET
proto-oncogene are associated with MEN-2A.47 Genomic studies in
pancreatic NETs by Jiao et al. revealed mutations in mTOR pathway
genes in 15% of patients,48 which provides a rationale for the
therapeutic use of mTOR inhibitors in this tumor type.49
NETs are also highly vascularized, which makes inhibition of vascular
endothelial growth factor (VEGF) signaling a relevant treatment option.
The VHL gene is associated with the regulation of hypoxia-inducible
factor (HIF); loss of VHL gene expression, which leads to constitutive
HIF activation and increased expression of HIF targets, such as VEGF,
has been linked to the development of pancreatic NETs.50
Mutational analysis of pulmonary NENs has also demonstrated
multiple genetic aberrations, including FGF2 mutations in large-cell
NEC; KIT, PTEN, HNF1A, and SMO alterations in atypical
carcinomas; JAK3, NRAS, RB1, and VHL1 mutations in SCLC ;and
SMAD4 mutations in typical carcinoids.51
Table 1. WHO Classification for NETs of the Lung and Thymus
Grade Nomenclature in Use Mitotic Count (per 10 HPFs) Necrosis
G1 Carcinoid b2 0
G2 Atypical carcinoid 2-10 Foci
G3 Poorly differentiated NEC N10 Present
Table 2. WHO Classification for NENs of the GI Tract




Figure 1. NETs may be divided by site of origin: foregut, midgut,
and hindgut.
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Types and Clinical Features
GEP-NETs
GEP-NETs, which characteristically present at age 50-60,52 are
challenging to diagnose, particularly if asymptomatic, which is often
the case, with incidental discovery usually during surgery for another
reason (e.g., appendectomy).53 If symptoms such as abdominal
discomfort are present, they are usually vague and nonspecific, which
may cause considerable delay and difficulty in diagnosis. GEP-NETs
are subdivided into two categories: carcinoid tumors of the luminal
GI tract and pancreatic NETs.
a. Appendiceal NENs54
The diagnosis of these tumors is usually established postoperatively
in the specimens of appendectomies. The majority of these tumors are
benign. Carcinoid syndrome is rare (b1%). A large female
preponderance is reported possibly due to a selection bias: higher
rates of diagnostic laparoscopy are performed in premenopausal
women who present with lower abdominal pain to distinguish
between a broad range of gynecologic and nongynecologic conditions.
b. Gastric NENs55,56
These rare tumors are classified into three types: Type I is associated
with chronic atrophic gastritis type, with or without pernicious anemia.
Type II is associated with Zollinger-Ellison syndrome and MEN-1
syndrome (see pancreatic NENs below). Type III tumors are sporadic,
large, solitary, and invasive tumors that occasionally produce an atypical
carcinoid syndrome mediated by histamine and serotonin. In contrast
to the diffuse rash of typical carcinoid syndrome, the flush with Type III
tumors is patchy red, serpiginous, and intensely pruritic.
c. Colorectal NENs
These rare tumors are associated with a more aggressive clinical
course and a poorer prognosis than adenocarcinomas.57 They are
subclassified into two pathological types: small-cell carcinomas and
moderately differentiated NECs.58 Small-cell carcinoma of the colon
and rectum shares similar morphologic and immunohistochemical
features with small-cell lung cancer, while moderately differentiated
NEC of the colon and rectum has a similar morphology to large-cell
lung carcinoma with neuroendocrine features. The former is managed
with chemotherapy; the latter, with surgery.
d. Pancreatic NENs (traditionally called islet-cell carcinomas)
These tumors involve pancreatic islet cells that may or may not
produce various hormones; the functional tumors that are associated
with a variety of clinical syndromes include:
• Insulinomas, a β-cell neoplasm of the pancreatic islets, and the
most common GI NET, which may appear as part of the MEN-1
syndrome, are responsible for excessive insulin secretion, leading to
symptoms of hypoglycemia and hypokalemia since insulin shifts
extracellular K into the intracellular compartment.59
• Gastrinomas, the second most common GI NET behind
insulinomas, are usually located in the pancreas and duodenum;
they occur predominately in older males and are responsible for
Zollinger-Ellison syndrome or severe peptic ulcer disease, often
in the absence of obvious risk factors such as nonsteroidal
anti-inflammatory drug intake, due to hypersecretion of acid from
uncontrolled production of the peptide hormone gastrin.
Twenty-five percent of gastrinomas are associated with MEN-1
syndrome.60,61
• Pancreatic polypeptide-secreting tumors (Ppomas) are the third
most common type of pancreatic NET. Unlike gastrinomas,
vasoactive intestinal peptide–secreting tumors (VIPomas), or
glucagonomas, no clinical syndrome is associated with these.
Ppoma patients present with weight loss, jaundice, and
abdominal pain. Elevated pancreatic polypeptide levels confirm
the diagnosis.62
• VIPomas, which arise from the pancreas in 90%63 of adult cases,
autonomously secrete VIP,64 leading to a syndrome initially
described by Verner and Morrison in 1958 of watery diarrhea,
hypokalemia, and achlorhydria.65 Like gastrinomas, insulinomas,
glucagonomas, and somatostatinomas, VIPomas are associated
with MEN-1 syndrome.66
• Glucagonomas are extremely rare pancreatic tumors that
overproduce the counterregulatory hormone glucagon. Gluca-
gonoma syndrome is a paraneoplastic phenomenon with an
estimated incidence of 1 in 20 million, characterized by the
presence of the 4 D's: diabetes, dermatitis (necrolytic migratory
erythema), deep vein thrombosis, and depression.67
• Somatostatinomas are the least common NET primarily located
in the pancreas and duodenum. Somatostatin is an inhibitory
hormone that suppresses pancreatic, biliary, gastric, and
intestinal secretions as well as gallbladder contractility. The
triad of cholelithiasis, hyperglycemia, and steatorrhea character-
izes somatostatinoma syndrome.68 An elevated somatostatin
level (N10 ng/ml) confirms the diagnosis.
Carcinoid Syndrome
The presence of carcinoid syndrome that results from the
hypersecretion of amines and peptides often facilitates diagnosis of
a NET. The enterochromaffin or Kulchitsky cells,69 which are part of
the diffuse neuroendocrine cells of the gut, synthesize serotonin from
dietary tryptophan.
The classical carcinoid syndrome with watery diarrhea, flushing,
bronchospasm, hypotension, and right-sided heart disease correlates
with serotonin hypersecretion since properties of serotonin include
vasodilation, bronchoconstriction, and smooth muscle contraction.70
Serotonin receptors71 are also expressed on the subendocardial cells of
heart valves, and elevated serum levels induce valvular disease.72
Involvement of the left side of the heart is uncommon due to
metabolism of the serotonin during passage through the lungs.73
Because the serotonin from small bowel tumors is drained by the
portal vein and inactivated by monoamine oxidases in the liver before
it reaches the systemic circulation, carcinoid syndrome74 usually only
occurs in the presence of liver or other distant metastases when the
serotonin bypasses hepatic metabolism.75 Confirmation of the
diagnosis is based on the measurement of urinary 5-hydroxyindole
acetic acid (5-HIAA), a serotonin metabolite, and plasma CgA,76,77 a
glycoprotein that is secreted with serotonin. Hypoproteinemia is
usually coincident with carcinoid syndrome due to depletion of
tryptophan, an essential amino acid.78 Since niacin (nicotinic acid)
production is dependent on tryptophan, pellagra-like symptoms
(diarrhea, dermatitis, and dementia) indicative of niacin deficiency
are common.79
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NENs of the Genitourinary (GU) Tracts
These rare neoplasms, which occur primarily in the kidney and urinary
bladder and usually present with abdominal or flank pain, abdominal
mass, weight loss, and hematuria,80 are more common in the female
than themaleGU tracts. In the genital tract of females, themost frequent
site is the cervix, followed by the ovaries. NENs of the endometrium,
vagina, and vulva have also been reported. Male GU neoplasms are even
rarer. The prostate is the most common site. Other tumor locations
include the testicles and small-cell NE carcinomas of the scrotum, penis,
and penile urethra. Symptoms due to hormone production or carcinoid
syndrome are rare, occurring in b10% of cases.81,82
Pulmonary NETs
NETs of the lung comprise typical carcinoid, atypical carcinoid,
LCNEC, and SCLC in order of worsening prognosis.83 They arise
from the amine precursor uptake decarboxylation system and share
the same neuroendocrine (Kulchitsky) cell of origin with small-cell
carcinoma of the lung.84 The clinical presentation (i.e., signs and
symptoms) varies depending on the anatomical location of the tumor
and the biological aggressiveness85 (Table 3).
At the more benign end of the spectrum, typical carcinoids, which
comprise approximately 2% of lung NETs, tend to occur in younger
patients (mean age, 45-50 years), with no significant predilection for
gender or smoking history.86 Signs and symptoms of centrally located
carcinoids (the majority) include recurrent infections, chest pain,
cough, wheeze, dyspnea, and pneumonia. Peripherally located
carcinoids (the minority) are generally asymptomatic and tend to
present incidentally.87 Compared with GEP-NETs, ectopic hormone
secretion and paraneoplastic syndromes such as Cushing's syndrome
are more rare.88 Carcinoid syndrome is almost exclusively seen in the
context of liver metastases.73
Unlike typical carcinoids, atypical carcinoids, which comprise 0.2%
of lung NETs, are associated with a history of smoking and occur more
frequently in men.89 The average age for an atypical carcinoid patient is
also about 10 years older (59 years in atypical carcinoids and 49 years in
typical carcinoids).90,91 Given their more common peripheral location,
atypical carcinoids tend to present later with symptoms than typical
carcinoids. The incidence of carcinoid syndrome is reportedly higher,
consistent with their propensity for metastasis.92
At the other end of the clinical spectrum is SCLC, by far the most
common lung NET (frequency of 20%,93 which has decreased in the
United States to 13%94), with a survival typically measured in
months.86 SCLC, which is invariably associated with tobacco use,
occurs predominately in older male patients (mean age, 65 years).95
The association with heavy smoking is so well established that
diagnosis in a lifetime nonsmoker is distinctly unusual and suspect.96
Fatigue, cough, dyspnea, decreased appetite, weight loss, pain, and
hemoptysis are the most common presenting symptoms.97 Extensive
enlargement of mediastinal and hilar lymph nodes are typically visible
on computed tomography (CT).98 Metastases at the time of
presentation to extrathoracic locations such as the bone, brain, liver,
and adrenals are the rule.98 Several paraneoplastic syndromes have been
associated with SCLC: syndrome of inappropriate antidiuretic
hormone, Cushing's syndrome, and neurologic paraneoplastic syn-
dromes such as autoimmune neuropathies and encephalomyelitis.97
LCNEC shares a similar clinical presentation and natural history to
SCLC with some exceptions: 1) primary LCNECs tend to occur
peripherally rather than centrally,99 and 2) presentation of LCNECs
with limited stage disease is more common than for SCLC
(approximately 25% versus less than 5%). LCNEC patients are
predominately male, and the median age is approximately 60 years.100
Paraneoplastic syndromes are rare.101
Tumor Localization
To investigate NENs, several imaging methods are available including
CT, magnetic resonance imaging, ultrasonography, scintigraphy, and
positron emission tomography. Tumor localization is essential since
surgery remains the optimal treatment in nonmetastatic disease.102
The first-line imaging investigation in most patients with suspected
bronchial NENs is chest radiography,103 which is abnormal in 90%
of patients, even though CT or magnetic resonance imaging is more
sensitive and bronchoscopy provides the opportunity for biopsy.83
These tumors, which tend to appear as circumscribed, centrally
located lesions, are associated with radiographic findings of
postobstructive pneumonia or mucus plugging.104
GI endoscopy is the procedure of choice to diagnose rectal,
duodenal, colonic, and gastric NETs.105 In the early stages, small
bowel tumors, in particular, are challenging to detect since they are
typically small and confined to the intestinal wall. When barium
studies or CT is inconclusive, angiography may be preferred because
these tumors are hypervascular.51 Magnetic resonance imaging, CT
scan, and ultrasonography are highly sensitive for the detection of
liver metastases but generally have a lower sensitivity for the
identification of extrahepatic sites.106
Since GEP-NENs generally express somatostatin receptors107 and
since octreotide, the somatostatin mimic, which can be labeled with
radionuclides such as 123-I or 111In, binds with high affinity to
somatostatin receptors, somatostatin receptor scintigraphy is a sensitive
method for the detection of the primary tumor and its metastases.108
Tumor Markers
Commonly measured tumor markers in NENs include serum CgA
and5-HIAA, the final secreted product of serotonin, levels in a
24-hour urine sample.109 Since serum CgA, which is a more sensitive
and broadly applicable marker than urinary 5-HIAA, does not depend
on serotonin secretion, it is preferred over 5-HIAA for bronchial and
rectal tumors, which do not generally secrete serotonin.110
In addition to its value in making the diagnosis, plasma CgA levels
correlate with tumor bulk, differentiation, and secretory activity, which,
in turn, may predict treatment response111 and overall survival (OS) (fast
rising levels seem to indicate a poor prognosis).112Besides CgA and
5-HIAA,NENs are known to produce a plethora of bioactive amines and
peptides such as 5-hydroxytryptamine, 5-hydroxytryptophan, serotonin,
insulin, gastrin, glucagon, somatostatin, vasoactive intestinal peptide,
growth hormone, adrenocorticotropic hormone, melanocyte-stimulating







Differentiation grade Low Intermediate High High
Mitotic count per 10 HPF fields
(diameter with a ×40 objective)
b2 2-10 N10 N10
Necrosis Absent Focal Extensive Extensive
Lymph node metastases at diagnosis 10%-15% 50% 60%-80% 60%-80%
Distant metastases at diagnosis 3%-5% 20%-25% 40% 60%-70%
Association with smoking No Yes Yes Yes
Paraneoplastic syndromes + ++ + ++++
Common anatomical location
in the lung161
Central Peripheral Peripheral Hilar/perihilar
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hormone, pancreatic polypeptide, calcitonin, substance P, pancreastatin,
etc., resulting in relatively uncommon but unique clinical syndromes.113
Oncologic Management
As a heterogeneous and complicated tumor type, NENs require
multidisciplinary care, inclusive of medical and radiation oncologists,
surgeons, pathologists, endocrinologists, interventional radiologists,
and possibly pulmonologists and gastroenterologists (Figure 2). In
general, a two-tiered grading criteria dictate treatment even though
the correspondence between histology and clinical behavior is in some
cases imperfect, leading to a gray area not backed by clear guidelines
or definitions.
Low-to-Intermediate NENs
The mainstay of treatment is surgery with curative intent, if
possible; the need for adjuvant therapy is questionable.114 However,
if surgery is not possible due to the extent and spread of disease, since
most NETs are diagnosed after metastases have already developed,
chronic medical management to both relieve symptoms and suppress
tumor growth and spread is required.115 Surgery may still be
indicated for palliative debulking to decrease tumor burden or help
control hormone production. If feasible, complete metastectomy,
especially when liver lesions are present, has been advocated.116
Another option with neuroendocrine liver lesions, given that the
majority of them are hypervascular, is hepatic directed procedures,
which include ablative therapy, transarterial embolization, transarter-
ial chemoembolization, and selective internal radiation therapy with
yttrium-90 microspheres.117
Systemic, i.e., nonsurgical non–liver directed, options approved
include somatostatin analogs, peptide receptor radionuclide therapy
(PRRT), low-dose interferon, everolimus, sunitinib, bevacizumab,
and cytotoxic regimens.118,119
a. Somatostatin analogs (SSAs)
Due to its extremely short half-life, on the order of 2 to 3minutes, the
peptide hormone somatostatin was never developed for use in the
clinic.120 However, the synthetic longer-acting analogs octreotide and
lanreotide were approved for the treatment of GEP tumors. Originally
dosed tomanage or prevent symptoms of hormone excess from carcinoid
syndrome, the improvement in progression-free survival (PFS) from two
placebo-controlled international studies (PROMID, using Octreotide,
and CLARINET trial, using Lanreotide) in patients with unresectable or
metastatic small bowel NETs established these SSAs as first-line agents
for low-grade NETs.121 However, due to a weak evidence base and
uncertainty in clinical practice guidelines, the optimal management
strategy after progression on first line SSAs is undefined.
b. PRRT
Since the majority of GEP-NENs express somatostatin receptors,
which are visualizable with diagnostic gallium or indium somatostatin
positron emission tomography tracers, a subsequent step was to use
the same receptor binding with radioactive isotopes such as yttrium-90
and/or lutetium-177 for treatment purposes.122 This so-called PRRT is
not yet approved in theUnited States,123 although it is readily available in
Europe and Asia under local regulations. Results from recently completed
phase 3 NETTER-1 study124 of 177Lu-DOTATATE (Lutathera) plus
the somatostatin octreotide LAR, the current standard of care in
GEP-NENs, versus octreotide LAR alone in patients with inoperable,
progressive, somatostatin receptor–positive midgut (i.e., jejunum, ileum,
appendix, and proximal colon) tumors demonstrated a clinically
meaningful and statistically significant increase in PFS and objective
response rate as well as the suggestion of a survival benefit (OS data are still
immature) on the Lutathera cohort. In April 2015, the FDA granted
fast-track designation to Lutathera.
c. Interferon alpha (IFN-α)
Early trials of IFN-α in hormonally functionalNETs took place prior
to the introduction of SSAs as first-line therapy; reduction of hormone
output, resulting in significant palliation of symptoms such as flushing
and diarrhea as well as improvement of tumor markers, was reported in
over 50% of patients.125,126 Objective tumor response rates were on the
order of 4% to 10%, with high rates of disease stabilization.
A suggestion of synergy between SSAs and IFN-α in small phase 1
studies resulted in three randomized clinical trials investigating SSAs
alone versus in combination with IFN-α. In two of these studies, which
compared subcutaneous octreotide alone to a combination with IFN-α,
the 5-year survival rate was improved in the combination group;
however, the differences were not statistically significant.127,128
Therefore, while IFN-α may be associated with an OS advantage, no
definitive conclusions can be drawn. Moreover, the potential for side
effects such as fevers, chills, myalgias, depression, andmyelosuppression
have limited its use in practice.129
d. Everolimus
Multiple lines of evidence implicate aberrant signaling through the
mechanistic pathway of rapamycin (mTOR) pathway to the
development of NETs.130 Additionally, altered expression of
mTOR pathway components is associated with poorer clinical
outcomes (e.g., PFS and OS). Therefore, the mTOR pathway has
emerged as a promising therapeutic target.
In a randomized phase II trial called RADIANT-2, which evaluated
the combination of the mTOR inhibitor everolimus and octreotide LAR
versus octreotide LAR in 429 patients with advanced, progressive NET
with carcinoid symptoms, median PFS was 16.4 months for the
Figure 2. Neuroendocrine multidisciplinary team.
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combination compared with 11.3 months for octreotide LAR alone;
while these results were not statistically significant, possibly due to a
highly heterogeneous patient population, the suggestion was that adding
everolimus to octreotide LAR leads to synergistic antiproliferative
activity.131 However, in a subgroup analysis of lung NETs from
RADIANT-2, everolimus + octreotide LAR was effective.
In the randomized phase III trial RADIANT-3, which compared
treatment with everolimus or matching placebo in patients with
advanced pNET, median PFS was 11 months in the everolimus arm
versus 4.6 months in the placebo arm, a highly statistically significant
difference that led to its approval in pNET.132,133
In the phase III trial called RADIANT-4, which randomized 302
patients with advanced, progressive nonfunctional NETs of the lungs and
GI tract 2:1 to either 10mg everolimus daily or placebo, median PFS was
significantly prolonged by 7.1 months and the risk of progression of the
disease was reduced by 52% in everolimus-treated patients.134
e. Sunitinib
Since NETs express VEGF and its receptor (VEGFR), sunitinib, a
small molecule that inhibits VEGFR1, VEGFR2, and VEGFR3, has
been tested in NETs. On the basis of an overall response rate of
16.7% in pNET patients and 2.4% in carcinoid patients in phase II, a
phase III randomized study of 37.5 mg of sunitinib daily versus
placebo in PNETs was initiated.135 The PFS of patients randomized
to the sunitinib arm was improved compared with those in the
placebo arm (11.4 months versus 5.5 months, hazard ratio 0.42,
P b .001), and the response rate was 9.3%, leading to FDA approval
for the treatment of metastatic pNETs.136
f. Bevacizumab
In a small phase II study, 44 patients were randomized to
octreotide plus bevacizumab versus octreotide plus interferon alfa-2b;
the bevacizumab arm demonstrated improved response rates and PFS,
suggestive of benefit.137 A randomized phase III cooperative group
(SWOG 0518) comparison of octreotide and bevacizumab with
octreotide and interferon alfa-2b in 400 carcinoid patients is ongoing.
A phase II study (CALGB 80701) of everolimus ± bevacizumab in
pNETs is also currently ongoing.138
g. Cytotoxic agents
The role of chemotherapy in advanced, well-differentiated NETs is
a subject of ongoing debate, with no accepted standard regimen. In
general, low-grade tumors are associated with a poorer response to
cytotoxic chemotherapy than high-grade tumors since the cells of
low-grade tumors divide more slowly. However, this relationship is
not absolute; low-grade tumors that exhibit a more aggressive pattern
of growth and/or symptomatic clinical course may be managed with
cytotoxic chemotherapy. While cytotoxic chemotherapy appears to
produce high response rates in metastatic pNETs, non-pNETs are
associated with lower response rates.139 The evidence base for the use
of chemotherapy in pNETs, GI-NENs, and bronchial (or thymic)
NENs is discussed below.
1. PNETs
The nitrosourea streptozocin (STZ) was the first agent to
demonstrate clinical effectiveness in PNETs. In the 1970s and
1980s, two randomized phase III trials that were based on
nonradiologic response criteria such as improvement in tumor
markers or reduction in hepatomegaly were conducted to confirm
promising phase II results with STZ monotherapy.140 The first of
these trials reported response rates of 63% with STZ plus
5-fluorouracil (5-FU) versus 36% with STZ monotherapy.141
The second trial reported response rates of 69% with STZ plus
doxorubicin versus 45% with STZ plus 5-FU.142 A more recent
retrospective study of STZ, 5-FU, and doxorubicin in metastatic
PNETs, which used objective radiologic response criteria, reported a
response rate of 39%.143
Single-agent dacarbazine (DTIC) is another cytotoxic with clinical
evidence of objective activity in metastatic pNETs, demonstrating a
response rate of 33% in a phase II trial. Nevertheless, these results
were offset by a high rate of toxicity.144 In fact, despite their activity,
the substantial toxicity profiles of both DTIC and STZ limit their
use in clinical practice.
A close relative of DTIC that also forms the DNA-alkylating
metabolite monomethyl triazeno imidazole carboxamide,145 oral
temozolomide is similarly active in metastatic pNETs but with less
toxicity. Combination regimens with thalidomide, everolimus, or
bevacizumab have shown response rates of 25% to 45%.146
However, the combination with capecitabine demonstrated the
most synergy in a 2011 study with a response rate of 70% and
overall PFS of 18 months.147 This synergy is schedule dependent,
with best results observed when capecitabine precedes temozolo-
mide, possibly due to partial depletion of levels of MGMT, a DNA
repair enzyme.148
2. GI-NENs
The role of chemotherapy in low- or intermediate-grade
gastrointestinal non-pancreatic neuroendocrine neoplasms (non-
pNETs) is less certain given the lower response rates that have been
observed in small clinical trials with streptozocin, 5-FU,
capecitabine, temozolomide, and doxorubicin.149 The general
consensus, however, is that chemotherapy should be reserved for
patients with no other therapeutic options. There are two notable
exceptions: Metastatic goblet-cell tumors of the appendix, which
express markers common to colorectal adenocarcinomas and,
therefore, may be treated with the same FOLFOX chemotherapy
regimen (5-FU, oxaliplatin, and leucovorin) used in colorectal
cancer. The ENETS Guidelines 2012 advocate for the use of
combination regimens incorporating a fluoropyrimidine.150
Rapidly progressive, aggressive disease, with early, distant spread
and behavior, on the whole, that is more similar to high-grade
NECs or SCLC, or uncontrolled symptoms related to hormone
secretion may warrant systemic chemotherapy such as platinum
doublets and/or radiotherapy.151
3. Bronchial and thymic NENs
Given their pathological similarities to small-cell lung cancer,
platinum-based doublets, mostly combinations with etoposide, are
commonly used despite poor response rates and treatment outcomes
since typical and atypical carcinoids tend to be less chemosensitive
than SCLC. While clinical data for these tumor types are scant
because they have not been studied independently of other NENs,
temozolomide has shown activity. Results from a published phase II
36-patient neuroendocrine study with oral temozolomide given for
5 consecutive days every 28 days yielded 4 partial responses (31%)
and 4 stable diseases (31%) among bronchial NENs and 5 stable
diseases (71%) among thymic NENs.152
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Extrapulmonary High-Grade Neuroendocrine Tumors (HGNECs)
Strictly speaking, HGNECs are rare, aggressive tumors typically
found in the GI and GU tracts and histologically defined by a high
mitotic rate (N10 mitotic figures per 10 high-powered fields or a
Ki-67 proliferative index N20%); their aggressive, rapidly progressive
behavior resembles small- or large-cell lung cancer,153 and treatment
is accordingly extrapolated from the treatment paradigm of SCLC.39
However, a subset of histologically low-grade, well-differentiated, or
intermediately differentiated tumors follows a rapid clinical course with
a biologically aggressive pattern of spread and proliferation that is
reminiscent of high-grade NETs; in these cases, histology correlates less
with grade than with stage; moreover, on the prima facie premise that
what looks, acts, and quacks like a duck actually is a duck, it may be
more appropriate to define and treat these tumors as HGNECs rather
than NENs. Indeed, Sorbye et al. contend that tumors once considered
“moderately differentiated” or “intermediate grade” have been de facto
migrated to the same category as small-cell carcinomas.39
Tang et al. further blurred the boundaries between low- and high-grade
tumors with a pathology study of 31 well-differentiated neuroendocrine
tumors, which concluded, “…the current WHO G3 category contains
both WD [well-differentiated]-NETs as well as PD-NECs (poorly
differentiated neuroendocrine carcinomas).” The chief finding from the
study is that tumors classified as well-differentiated constitute an
inhomogeneous group, which may 1) undergo phenotypic progression
and transform from low-grade to high-grade as they metastasize and 2)
contain focal areas of poorly differentiated cells.154
For metastatic disease that is classified as high grade on the basis of
either histological characteristics or aggressive biological behavior,
first-line treatment consists of platinum-based chemotherapy with
response rates that range from 42% to 67% and a median survival of 15
Figure 3. An algorithmic overview for the investigation and treatment of NENs.
998 Nothing But NET Oronsky et al. Neoplasia Vol. 19, No. xx, 2017
to 19months.155,156 Temozolomide is generally given in second line on
the basis of a 25-patient NEC study where the response rate for
temozolomide with or without capecitabine and bevacizumab after
progression on cisplatin-based chemotherapy was 33% and the median
OS was 22 months.157 Topotecan has also been recommended in
second line based on extrapolation from treatment of SCLC, but no
independent confirmation of its activity in this setting is available.
Clinical trials with sunitinib and everolimus are reportedly under way,
but no results have been reported.39
A newcomer to the treatment of high-grade NECs that deserves brief
mention due to the uniqueness of its chemical structure, mechanism of
action, and provenance, having been “spun off” from aerospace and
defense research and development, which completely sets it apart from
other so-called “targeted” agents such as everolimus and sunitinib, is the
experimental epi-immunotherapeutic anticancer agent RRx-001.158
Several published case reports have described clinical benefit (prolonged
stable disease for over a year and improvement in carcinoid syndrome in
HGNECs) and 3/4 durable partial responses in SCLC with RRx-001 in
the context of a phase II clinical trial called QUADRUPLE THREAT
(NCT02489903159–161).
An algorithmic approach to the evaluation and treatment of NETs
is provided in Figure 3.
Conclusion
NETs, a heterogeneous population of cancer subtypes and morphol-
ogies ranging from NENs and pNETs to small-cell lung cancer and
large-cell NECs, are historically lumped together as a homogeneous
group under one umbrella term on the basis of a single shared variable,
the expression of neuroendocrine markers, such as CgA and Syn, which
may or may not impact treatment management or clinical prognosis.
However, as a generic label of convenience, “neuroendocrine”may do
more harm than good since it implies biologically “benign” behavior for
tumors that are not reproducibly or reliably indolent; in fact, so-called
well- or moderately differentiated NENs may, in some cases, defy their
grade 1 or 2 histological classification and act more like grade 3 tumors
instead of low-risk, slow-growing ones, with widespread and eventually
fatal metastases. In these cases, based on their highly aggressive behavior,
possibly secondary to evolution with higher-grade transformation of the
original low-grade disease, as demonstrated by the previously discussed
2016 pathologic study of Tang et al., it may be more appropriate to
reclassify these tumors as SCLC variants and treat them accordingly with
platinum doublets rather than with analogs of somatostatin.153
In the final analysis, however they are ultimately defined, NENs
and carcinomas, as zebras of the oncology world that are fraught with
heterogeneity, constitute a clinical conundrum, intrinsically complex
and rendered even more so by a confused and cumbersome
terminology, which is anathema to standardization and uniformity
of treatment and outcome. Fortunately, a renaissance of chemother-
apeutic agents, small molecules, and biological therapies that have
progressed to clinical trials presages progress (and hope) in the
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